Page 48 - Priority Review News Today

Bracco Imaging has issued a statement on new results published in the journal Radiology which found that gadopiclenol (VUEWAY), which has half the dose (or the amount) of gadolinium found in other available gadolinium-based contrast agents, provides similar lesion visualization and contrast enhancement compared with gadobuterol (Gadavist).

RYSTIGGO is now commercially available by prescription in the United States for adult patients with gMG who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody...

First and only FLT3 inhibitor approved across three phases of AML treatment based on QuANTUM-First results demonstrating VANFLYTA added to chemotherapy improved overall survival Third innovative...

The results of the multicenter, international PROMISE clinical trial demonstrate that gadopiclenol provides similar lesion visualization and contrast...

APLS | Complete Apellis Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

FDA approves Beyfortus™ to protect infants against RSV disease Beyfortus™ is the first monoclonal antibody approved to protect all infants through their first RSV seasonAcross all clinical...

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

To celebrate the first half of 2023, we are recapping the top FDA approvals through June 2023 from within the HCPLive Network of brands.

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA)...